Physician profile
Amit Shetty
NPI 1801283890
$2,132.99
in general payments reported to CMS, 2019-2025
16 companies · $671 in 2025
The $671 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $193 · 2023: $314 · 2024: $955 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,599 · Long Term Medical Supply Or Device Loan: $241 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,599.08 |
| Long Term Medical Supply Or Device Loan | $240.85 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $588.16 | 2022-2025 | Fasenra, Tagrisso, Breztri |
| Integra Lifesciences Corporation | $284.40 | 2022-2024 | Acell, Integra, Primatrix |
| Merck Sharp & Dohme LLC | $271.51 | 2022-2025 | Zerbaxa, Dificid, Recarbrio |
| Boston Scientific Corporation | $194.61 | 2024 | Wavewriter Alpha Prime 16 |
| Mallinckrodt Hospital Products INC. | $179.44 | 2022-2025 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $118.41 | 2023-2025 | Glassia |
| Glaxosmithkline, LLC. | $111.26 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Viatris Specialty LLC | $81.50 | 2025 | Yupelri |
| Verona Pharma, INC. | $66.30 | 2025 | Ohtuvayre |
| Pfizer INC. | $56.08 | 2024-2025 | |
| Mylan Specialty L.P. | $52.88 | 2024 | Yupelri |
| United Therapeutics Corporation | $48.79 | 2025 | Tyvaso |
| Alexion Pharmaceuticals, INC. | $29.12 | 2025 | Ultomiris |
| Amgen INC. | $18.42 | 2025 | Uplizna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.62 | 2023 | Stiolto Respimat |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $15.49 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Shetty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.